Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

Heinz Ludwig*, Thomas Melchardt, Siegfried Sormann, Martin Schreder, Johannes Andel, Bernd Hartmann, Christoph Tinchon, Niklas Zojer, Eberhard Gunsilius, Klaus Podar, Alexander Egle, Wolfgang Willenbacher, Ewald Wöll, Reinhard Ruckser, Boris Bozic, Maria-Theresa Krauth, Andreas Petzer, Clemens Schmitt, Sigrid Machherndl-Spandl, Hermine AgisMichael Fillitz, Song-Yau Wang, August Zabernigg, Stefan Knop, Bruno Paiva, Richard Greil

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Letter/short communication

Abstract

Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.

Original languageEnglish
Pages (from-to)1008-1011
Number of pages4
JournalAmerican Journal of Hematology
Volume99
Issue number5
Early online date29 Feb 2024
DOIs
Publication statusE-pub ahead of print - 29 Feb 2024

Keywords

  • Lenalidomide/therapeutic use
  • Dexamethasone/therapeutic use
  • Humans
  • Induction Chemotherapy
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Multiple Myeloma/diagnosis

Fingerprint

Dive into the research topics of 'Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this